Clinical Trial: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07504458) titled 'Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia' on March 16.

Brief Summary: This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Acute Promyelocytic Leukemia (APL) Acute Promyelocytic Leukaemia Acute Promyelocytic Leukemia With PML-RARA Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA Acute Promyelocytic Leukemia

Intervention: DRUG: QTX-2101 + ATRA

The expe...